Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
A prospective, multicenter study of 332 patients with schizophrenia or depression assessed the safety and effectiveness of the laxative elobixibat in real-world settings between June 2018 and May 2022. Adverse drug reaction rates ranged from 2.33% to 9.09%, with diarrhea being the most common, and no serious ADRs were reported. Mean weekly defecation frequency increased from approximately 3 at baseline to over 5 after 4 weeks of treatment, and the proportion of patients with ideal stool form scores reached about 60% by week 52.
Primary data file is a DOCX document (688.3 KB), which may require parsing to extract structured data.